Publicacións en colaboración con investigadores/as de Hospital Universitario San Juan de Alicante (42)

2024

  1. Classification tree obtained by artificial intelligence for the prediction of heart failure after acute coronary syndromes

    Medicina Clinica, Vol. 163, Núm. 4, pp. 167-174

2023

  1. Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome

    Thrombosis Research, Vol. 224, pp. 46-51

  2. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  3. Remnant cholesterol in patients admitted for acute coronary syndromes

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 340-348

  4. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

    Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  3. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  4. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2021

  1. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events

    Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169

  2. Managing NSTEMI in older patients

    The Lancet

  3. Mortality associated with cardiovascular disease in patients with COVID-19

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38

  4. New-onset heart failure after acute coronary syndrome in patients without heart failure or left ventricular dysfunction

    Revista Espanola de Cardiologia, Vol. 74, Núm. 6, pp. 494-501

2020

  1. Estimation of the major cardiovascular events prevention with Inclisiran

    Atherosclerosis, Vol. 313, pp. 76-80

  2. Long-term bleeding risk vs. mortality risk in acute coronary syndrome patients according to the 2019 ARC-HBR definition

    Thrombosis Research

  3. Prediction of major adverse cardiac, cerebrovascular events in patients with diabetes after acute coronary syndrome

    Diabetes and Vascular Disease Research, Vol. 17, Núm. 1

  4. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials

    Journal of Diabetes and Metabolic Disorders, Vol. 19, Núm. 2, pp. 759-765

  5. Sex-related differences in long-term mortality and heart failure in a contemporary cohort of patients with NSTEACS. The cardiochus-HSUJ registry

    European Journal of Internal Medicine, Vol. 81, pp. 26-31

2019

  1. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population

    International Journal of COPD, Vol. 14, pp. 371-380

  2. Clinical impact of mineralocorticoid receptor antagonists treatment after acute coronary syndrome in the real world: A propensity score matching analysis

    European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 7, pp. 652-659